NXTCL’s Cellaviva brand is expanding into Denmark
NextCell Pharma AB ("NXTCL") announced today, that the Cellaviva brand will expand its operations into Denmark. As of 1st October 2018, Cellaviva will offer family stem cell banking there. The idea of family saving of stem cells is already an established business in Denmark and NXTCL estimates that its entrance into Denmark will allow for a doubling of annual sales for Cellaviva. The establishment fits within the existing budget and does not affect NXTCL's capital requirements.
Cellaviva has now decided to expand its operations to Denmark as of 1st October 2018. The company holds all the necessary permits required to run a tissue establishment with collection of samples in both Sweden and Denmark. Cellaviva has a contract in place with midwives based in Denmark, who will be responsible for the activities on the Danish market. Family saving of stem cells is an established business in Denmark and since family saving of stem cells was first marketed in Denmark 15 years ago, several thousand parents have chosen to save their newborn child's stem cells. The board estimates that the expansion will allow for a doubling of annual sales for Cellaviva.
CEO Mathias Svahn comments
"The right time for Cellaviva’s expansion is now. Starting today we can offer family stem cell saving on the Danish market. We have already been contacted by customers asking for our services. Stem cell saving from birth is more common in Denmark than in Sweden and we estimate that we will be able to get a large number of customers."
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 01th of October 2018.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.